Medical device major, Medtronic, Inc. (MDT), recently reported the registration and surgical implant of the first patient in its global clinical study – WRAP Infection Clinical Trial.
The primary aim of this trial is to estimate the efficiency of Medtronic's TYRX Absorbable Antibacterial Envelope in minimizing major infections in roughly 7,000 patients grafted with cardiac implantable electronic devices (CIEDs), who are at risk of infection.
The secondary aim of this study involves evaluating healthcare costs related to the treatment of CIED patients who suffer from major infection, at the 225 sites across the globe that have been assigned for this study.
Medtronic's TYRX Absorbable Antibacterial Envelope has been designed to contain a CIED, in order to offer a stable environment when implanted in a patient’s body. Once implanted, this sterile prosthesis releases antimicrobial agents at the surgical site over a minimum of 7 days, to help prevent infection.
The envelope stabilizes the CIED, and then dissolves and gets fully absorbed approximately nine weeks after implantation.
In Jan 2014, Medtronic acquired New Jersey-based TYRX which is a FDA-registered medical device manufacturer of drug-device combination products utilizing the novel polymer technology and the original developer of TYRX Absorbable Antibacterial Envelope .
Per Medtronic's management, with respect to CIED implanted patients who are mostly at low risk of infection, the TYRX envelope provides an additional protective layer and eases a physician's task to provide safer implantation through a cost-efficient procedure.
Medtronic's oldest and largest segment – Cardiac Rhythm & Heart Failure – which incorporates this absorbable mesh envelope, had delivered positive growth of 5% in the last reported quarter. More importantly, this growth incorporated combined revenues of $18 million earned from the company's acquisition of TYRX, Corventis and NGC Medical.
Currently, Medtronic carries a Zacks Rank #3 (Hold). Better-ranked medical product stocks include ICU Medical, Inc. (ICUI), INSYS Therapeutics, Inc. (INSY) and Conatus Pharmaceuticals Inc. (CNAT). While ICU Medical and INSYS Therapeutics sport a Zacks Rank #1 (Strong Buy), Conatus Pharmaceuticals holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment